Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment

Expert Opinion on Orphan Drugs

Volumn 1, Issue 6, 2013, Pages 437-443

  Van Rijswijk, Henricus N A J ^a,b   Vorselaars, Adriane D M ^a   Ruven, Henk J T ^a   Keijsers, Ruth G M ^a   Zanen, Pieter ^c   Korenromp, Ingrid H E ^a   Grutters, Jan C ^a,c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti TNF ; Disease activity; Lung function; Quality of life; Sarcoidosis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; METHOTREXATE; PREDNISONE; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DIFFUSING CAPACITY OF THE LUNG FOR CARBON MONOXIDE CORRECTED FOR HEMOGLOBIN CONCENTRATION; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; EXERCISE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG PARENCHYMA; LUNG SARCOIDOSIS; MALE; MEDIASTINUM; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; SCORING SYSTEM; SHORT FORM 36; SMALL FIBER NEUROPATHY; TREATMENT INDICATION; UVEITIS; VITAL CAPACITY;

EID: 84896692122     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.797891     Document Type: Article

References (29)

1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65
2. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-18
3. American Thoracic Society. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Resp Care Med 1999;160:736-55
4. Judson MA, Baughman RP, Thompson BW, Two year prognosis of sarcoidosis. The ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20(3):204-11
5. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008;29:533-48
6. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006;28:627-36
7. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005(2):CD001114
8. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160:192-7
9. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60-6
10. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-81
11. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4
12. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71
13. Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
14. Chaudhari U, Romano P, Mulcahy LD, Efficacy and safety of infliximab for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271):1842-7
15. Maini R, st Clair EW, Breedveld F, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932-9
16. Baughman RP, Drent M, Kavuru M, Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802
17. Rossman MD, Newman LS, Baughman RP, A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis. Vasc Diffuse Lung Dis 2006;23:201-8
18. Judson MA, Baughman RP, Costabel U, Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial. Eur Respir J 2008;31:1189-96
19. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012;83:218-24
20. Keijsers RG, Verzijlbergen JF, van Diepen DM, 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:143-9
21. Keijsers RG, Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Resp J 2013;41(3):743-51
22. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 2010;31(4):409-18
23. Grutters JC, Felllrath JM, Mulder L, Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003;124(1):186-95
24. Kruit A, Grutters JC, Gerritsen WB, ACE I/D--corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007;101:510-15
25. Vercoulen JHMM, Alberts M, Bleijenberg G. De checklist individual strength (CIS). Gedragstherapie 1999;32:131-6
26. Ware J Jr, Sherbourne CD. The MOS 36 Item Short Form Health Survey (SF 36). 1. Conceptual framework and item selection. Med Care 1992;30:473-83
27. McHorney A, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993;31:247-63
28. Swigris JJ, Brown KK, Behr J, The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304
29. Baughman RP, Nunes H, Sweiss NJ, Established and experimental medical therapy of pulmonary sarcoidosis. Eur Res J 2013; Epub ahead of print